Review of maintenance of response to psoriasis treatments

Journal of Dermatological Treatment

Volumn 27, Issue 4, 2016, Pages 293-297

  Bartos, Simona ^a   Hill, Dane ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

health care delivery; long term; phase 3 trials; statistics; Treatment efficacy

Indexed keywords

ADALIMUMAB; APREMILAST; ETANERCEPT; INFLIXIMAB; SECUKINUMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; METHODOLOGY; PRIORITY JOURNAL; PSORIASIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL (TOPIC); FEMALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84978383950     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546634.2016.1177158     Document Type: Editorial

References (13)

1. K.A.Papp, S.Tyring, M.Lahfa,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12
2. C.West, S.Narahari, J.O'Neill,. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013;19:18182
3. J.Takeshita, S.Wang, D.B.Shin,. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. J Am Acad Dermatol. 2014;71:1167–75
4. A.Igarashi, T.Kato, M.Kato,. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242–52
5. C.L.Leonardi, A.B.Kimball, K.A.Papp,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet (London, England). 2008;371:1665–74
6. R.G.Langley, M.Lebwohl, G.G.Krueger,. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172:1371–83
7. A.B.Kimball, K.B.Gordon, S.Fakharzadeh,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166:861–72
8. A.Menter, S.R.Feldman, G.D.Weinstein,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1–15
9. A.B.Gottlieb, R.G.Langley, B.E.Strober,. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649–57
10. A.Menter, S.K.Tyring, K.Gordon,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15
11. P.Rich, B.Sigurgeirsson, D.Thaci,. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–11
12. U.Mrowietz, C.L.Leonardi, G.Girolomoni,. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.e1
13. K.Papp, K.Reich, C.L.Leonardi,. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49